A Study of LY3437943 in Participants With Type 2 Diabetes

The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin.

Trial Summary

Age Range
18 - 75 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
LY3437943, Dulaglutide
Could I receive a Placebo?
Yes
Enrollment Goal
281
Trial Dates
May 13, 2021 - Oct 27, 2022
How long will I be in the trial?
Your participation could last about 43 weeks and may include up to 14 visits to the study center.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have type 2 diabetes

  • Participants must have received metformin along with diet and exercise in the last 3 months

  • Participants must have stable body weight for the last three months

Participants Must Not:

  • Participants must not have type 1 diabetes

  • Participants must not have ketoacidosis

  • Participants must not have retinopathy, maculopathy
    - Participants must not have pancreatitis

  • Participants must not have high blood pressure

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources

Diabetes Research

To learn more about diabetes and clinical trials being carried out in this area, visit our Diabetes Research page.

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study. It helps us learn if a new medicine or treatment works and how it works. Clinical trials can also be called clinical research studies. Learn more about clinical research studies and what to expect when taking part in a clinical trial.